Publications & coverage

Primary sources.

Peer-reviewed research, independent coverage and interviews. Conclusions drawn in external articles are those of their authors, not of AEBi.

Peer-reviewed · MuTaTo2000

A Novel Concept for a Multi-Targeted Toxin (MuTaTo) Cancer Treatment Based on Peptide Targeting

The peer-reviewed outline of AEBi's multi-targeted cancer concept, in which several SoAP-derived targeting peptides are conjugated to a toxin so that a cancer cell cannot escape through mutation of a single receptor.

SCIRP — Open Access Library JournalOpen the paper

Press2019

Israeli cancer treatment could be something special

A biochemistry professor's assessment of the MuTaTo concept and the scepticism that met its announcement, published as a science column.

The Irish Times

Broadcast2019

Israeli company's new cutting-edge cancer treatment

A studio interview with AEBi's founder and CEO on the multi-targeting rationale behind MuTaTo and the path to clinical trials.

i24NEWS English

Broadcast2019

Cure for cancer? Israeli scientists say they may have found one

A health-desk segment explaining peptide targeting and the cautious view of the programme's early preclinical results.

WXYZ-TV Detroit, Channel 7

Feature2020

AEBi company feature — pages 16–19

A four-page profile of AEBi, the SoAP platform and the therapeutic programme in a life-science publication.

Samedan publication, via Calaméo

Press2019

Accelerated Evolution Biotechnologies claims to have a breakthrough cancer cure

An independent profile of AEBi's MuTaTo programme and the peptide platform behind it.

Next Big Future

Speaking2018

Keynote presentation, Munich

AEBi presented its screening platform and therapeutic programme to the European biotech community.

World BI Group

Collaboration

Media and scientific enquiries.

Interviews, data requests and copies of publications are handled directly by the scientific team rather than a press office.

Contact AEBi